Publication details
Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: A phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration
| Authors | |
|---|---|
| Year of publication | 2007 |
| Type | Article in Periodical |
| Magazine / Source | Clinical Therapeutics |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.clinthera.2007.08.002 |
| Field | ORL, ophthalmology, stomatology |
| Keywords | gacenoxacin acute bacterial maxillary sinusitis phase II multicenter study |
| Description | The aim of this study was to assess the efficacy and tolerability of garenoxacin in adults with acute bacterial maxillary sinusitis undergoing a pretreatment diagnostic sinus aspirate. Garenoxacin is a des-F(6)-quinolone with in vitro activity against key respiratory pathogens, including Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. This Phase II, multicenter, noncomparative, open-label study was conducted at 30 centers in the United States, Mexico, Argentina, and Europe. Conclusion: In this population of patients with signs and symptoms of acute maxillary sinusitis, oral garenoxacin 400 mg QD for 5 or 10 days eradicated 94 % of bacterial pathogens associated with acute bacterial sinusitis in this population and appeared to be well tolerated in adults. |